Abstracts may be submitted for oral and poster presentations for the following topics:
AS01 | PATHOGENESIS OF ATHEROSCLEROSIS |
AS01.01 | Endothelial cell function and biology |
AS01.02 | Smooth muscle cell biology |
AS01.03 | Macrophages in lipid metabolism and atherosclerosis |
AS01.04 | Inflammation, immunity and infection in atherosclerosis |
AS01.05 | Extracellular matrix and calcification |
AS01.06 | Vascular biology of the arterial wall |
AS01.07 | Imaging |
AS01.08 | Platelets, thrombosis and atherosclerosis |
AS01.09 | Aortic valve stenosis |
AS01.10 | Clonal Haematopoiesis |
AS01.11 | Plaque remodelling |
AS01.12 | Neuroimmune axis in atherosclerosis |
AS01.13 | Other |
AS02 | LIPIDS AND LIPOPROTEINS |
AS02.01 | Lp(a) |
AS02.02 | TG rich lipoproteins metabolism and lipases |
AS02.03 | HDL |
AS02.04 | Lipoprotein receptors |
AS02.05 | Bile acids |
AS02.06 | Cholesterol efflux and reverse cholesterol transport |
AS02.07 | Lipidomics and metabolomics |
AS02.08 | Cellular lipid metabolism and lipid droplets |
AS02.09 | Lipid and lipoprotein metabolism |
AS02.10 | Modified lipoproteins |
AS02.11 | Liver metabolism and steatosis |
AS02.12 | Adipose tissue biology and pathology |
AS02.13 | Incretins and lipid metabolism |
AS02.14 | Other |
AS03 | DYSLIPIDEMIA AND RISK FACTORS |
AS03.01 | Epidemiology of cardiovascular diseases and risk factors |
AS03.02 | Epidemiology of dyslipidemias |
AS03.03 | Diabetes, insulin sensitivity and resistance |
AS03.04 | Adipose tissue homeostasis |
AS03.05 | Inherited dyslipidemias |
AS03.06 | Gender and cardiovascular risk |
AS03.07 | Environmental risk factors |
AS03.08 | Novel risk factors and biomarkers |
AS03.09 | Epidemiology of socioeconomic and psychosocial risk factors |
AS03.10 | Gut microbiome |
AS03.11 | Gene editing technology |
AS03.12 | Genomics, GWAS and population genetics; Mendelian randomization |
AS03.13 | Epigenetics and microRNA |
AS03.14 | Gene-Environment interactions |
AS03.15 | Cardiometabolic factors implicated in the development of heat failure with preserved ejection fraction |
AS03.16 | Other |
AS04 | CLINICAL VASCULAR DISEASE |
AS04.01 | Coagulation and Thrombosis |
AS04.02 | Endothelial dysfunction; Clinical assessment |
AS04.03 | MAFLD, NASH and other ectopic lipid diseases |
AS04.04 | Chronic kidney disease and nephropathies |
AS04.05 | Diabetes; macro- and microangiopathies |
AS04.06 | Aneurysms and other non-atherosclerotic arteriopathies |
AS04.07 | Nutrition, nutraceuticals |
AS04.08 | Bariatric surgery |
AS04.09 | Lipid-lowering therapies |
AS04.10 | Anti-thrombotic therapies |
AS04.11 | Anti-inflammatory therapies |
AS04.12 | Prevention and treatment of cardiovasculardisease; miscellaneous |
AS04.13 | New lipid lowering therapies |
AS04.14 | SGTL2 inhibitor and cardiovascular diseases |
AS04.15 | Other |